-

XCUR Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Exicure, Inc. (XCUR)

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Exicure, Inc. (NASDAQ: XCUR) securities between March 11, 2021 and November 15, 2021, for violations of the Securities Exchange Act of 1934. Exicure is a clinical stage biotechnology company that develops therapeutics for neurology, immune-oncology, inflammatory diseases, and other genetic disorders based on its proprietary spherical nucleic acid technology.

If you suffered a loss due to Exicure, Inc.'s misconduct, click here.

Exicure, Inc. (XCUR) Failed to Disclose Improprieties Associated with its Preclinical Program for the Treatment of Friedreich's Ataxia

According to the complaint, defendants failed to disclose that there had been certain improprieties in Exicure's preclinical program for the treatment of Friedreich's ataxia and that there was a material risk that data from the preclinical program would not support continued clinical development.

On November 15, 2021, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report ended September 30, 2021. It explained it was investigating "a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company's XCUR-FXN preclinical program for the treatment of Friedreich's ataxia." On this news, the Company's stock price fell 28%, to close at $1.07 per share on November 16, 2021.

If you acquired shares of Exicure, Inc. (XCUR) securities between March 11, 2021 and November 15, 2021, you have until February 11, 2022, to ask the court to appoint you lead plaintiff for the class.

Representation is on a contingency fee basis. Shareholders pay no fees or costs.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Exicure, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investment Notice: Robbins LLP Informs Investors of the Megan Holdings Limited Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Megan Holdings Limited (NASDAQ: MGN) securities between September 26, 2025 and March 25, 2026, or acquired shares in connection with its initial public offering ("IPO") on September 26, 2025. The Company conducts its purported business operations in Malaysia and purportedly is principally engaged in the development, construction, and maintenanc...

Investor Notice: Robbins LLP Informs Investors of the Photronics, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Photronics, Inc. (NASDAQ: PLAB) securities between December 10, 2025 and May 27, 2026. Photronics is a global manufacturer of photomasks, which are microscopic circuit patterns contained on very precise glass or quartz plates, and which are a necessary element in the manufacturing of integrated circuits (“ICs”) and flat panel displays (“FPDs”)....

Investor Notice: Robbins LLP Informs Investors of the Insulet Corporation Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026. Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the U.S. and internationally. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The A...
Back to Newsroom